(6R,10bS)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (6R,10bS)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline
• 化学式: C₁₈H₁₈ClN
• 分子量: 283.8
• InChiKey: KWMNBUDYCCTHHL-AEFFLSMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Hexahydropyrrolo (2,1-a) isoquinoline derivatives
  申请人：McNeilab, Inc.

  公开号：EP0130069A2

  公开（公告）日：1985-01-02

  ovel compounds are disclosed, which are derivatives of 1, 2, 3, 5, 6, 10b-hexahydropyrrolo [2, 1-a]- isoquinolines, represented by general formula (I): as well as pharmaceutical compositions and methods for the treatment of depression in warm-blooded animals, e.g., man. Novel intermediates are also part of the invention.

  本研究公开了由通式（I）表示的 1、2、3、5、6、10b-六氢吡咯并[2，1-a]-异喹啉的衍生物以及用于治疗温血动物（如人类）抑郁症的药物组合物和方法： 以及治疗温血动物（如人类）抑郁症的药物组合物和方法。新型中间体也是本发明的一部分。
• Gaboxadol for treating depression and other affective disorders
  申请人：H. LUNDBECK A/S

  公开号：EP2145620A2

  公开（公告）日：2010-01-20

  The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.

  本发明涉及使用加博沙多制备治疗抑郁症的药物组合物。此外，本发明还涉及使用加博沙多制备药物组合物，该药物组合物可与血清素再摄取抑制剂或任何其他化合物结合使用，从而提高细胞外血清素的水平。
• Treatment of depression and other affective disorders
  申请人：Sanchez Connie

  公开号：US20050234093A1

  公开（公告）日：2005-10-20

  The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.

  本发明涉及使用加博沙多制备治疗抑郁症的药物组合物。此外，本发明还涉及将加保沙多用于制备与血清素再摄取抑制剂或任何其他可导致细胞外血清素水平升高的化合物联合使用的药物组合物。
• Combination therapy wherein a serotonin reuptake inhibitor is used
  申请人：Mork Arne

  公开号：US20050288355A1

  公开（公告）日：2005-12-29

  The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulsive control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.

  本发明涉及一种化合物（5-羟色胺再摄取抑制剂）和另一种化合物（GABAB 受体拮抗剂、反向激动剂或部分激动剂）在制备治疗抑郁症、焦虑症和其他情感障碍（如广泛性焦虑症、恐慌性焦虑症、强迫症、急性应激障碍、创伤后应激障碍和社交焦虑症）的药物组合物中的用途、强迫症、急性应激障碍、创伤后应激障碍和社交焦虑障碍、饮食障碍（如贪食症、厌食症和肥胖症）、恐惧症、癔症、经前综合征、认知障碍、冲动控制障碍、注意缺陷多动障碍、药物滥用或对血清素再摄取抑制剂有反应的任何其他障碍。
• Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
  申请人：Didriksen Michael

  公开号：US20060223857A1

  公开（公告）日：2006-10-05

  The present invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders. In particular the present invention relates to treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The present invention also relates to a pharmaceutical composition comprising a serotonin reuptake inhibitor, and a GlyT-1 inhibitor.

  本发明涉及一种化合物（5-羟色胺再摄取抑制剂）和一种化合物（GlyT-1抑制剂）用于制备治疗抑郁症、焦虑症和其他情感障碍的药物组合物。本发明尤其涉及抑郁症、焦虑症和其他情感障碍的治疗，如广泛性焦虑症、恐慌焦虑症、强迫症、急性应激障碍、创伤后应激障碍和社交焦虑症、进食障碍，如贪食症、厌食症和肥胖症、恐惧症、癔症、经前期综合征、认知障碍、冲动控制障碍、注意缺陷多动障碍、药物滥用或任何其他对血清素再摄取抑制剂有反应的障碍。本发明还涉及一种药物组合物，该组合物包含血清素再摄取抑制剂和 GlyT-1 抑制剂。